Kumar Prabhash

669 total citations
37 papers, 145 citations indexed

About

Kumar Prabhash is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Kumar Prabhash has authored 37 papers receiving a total of 145 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pulmonary and Respiratory Medicine, 15 papers in Oncology and 8 papers in Surgery. Recurrent topics in Kumar Prabhash's work include Lung Cancer Treatments and Mutations (10 papers), Head and Neck Cancer Studies (7 papers) and Lung Cancer Diagnosis and Treatment (4 papers). Kumar Prabhash is often cited by papers focused on Lung Cancer Treatments and Mutations (10 papers), Head and Neck Cancer Studies (7 papers) and Lung Cancer Diagnosis and Treatment (4 papers). Kumar Prabhash collaborates with scholars based in India, United States and United Kingdom. Kumar Prabhash's co-authors include Vanita Noronha, Vanita Noronha, Hemant Tongaonkar, Vikas Ostwal, Hari Menon, Siddharth Laskar, Reena Nair, Anil D′Cruz, Manju Sengar and Tanuja Shet and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Kumar Prabhash

28 papers receiving 135 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kumar Prabhash India 7 55 42 36 29 27 37 145
J Bolt Australia 5 34 0.6× 19 0.5× 61 1.7× 25 0.9× 28 1.0× 7 145
Sydney Akapame United States 8 183 3.3× 74 1.8× 48 1.3× 29 1.0× 10 0.4× 15 278
E. Pedrosa Spain 10 36 0.7× 51 1.2× 185 5.1× 33 1.1× 58 2.1× 15 370
Mehran Afshar United Kingdom 10 120 2.2× 77 1.8× 116 3.2× 10 0.3× 26 1.0× 32 258
Mariano Catello Di Donna Italy 11 127 2.3× 71 1.7× 37 1.0× 7 0.2× 21 0.8× 31 302
Aušvydas Patašius Lithuania 9 63 1.1× 96 2.3× 99 2.8× 53 1.8× 19 0.7× 38 258
Eric Brown United States 9 58 1.1× 40 1.0× 23 0.6× 12 0.4× 5 0.2× 16 206
Bin Lin China 5 29 0.5× 48 1.1× 91 2.5× 13 0.4× 26 1.0× 15 180
Olufunmilade Omisanjo Nigeria 6 41 0.7× 44 1.0× 81 2.3× 7 0.2× 14 0.5× 17 178
In‐Chang Cho South Korea 12 121 2.2× 46 1.1× 176 4.9× 25 0.9× 26 1.0× 42 364

Countries citing papers authored by Kumar Prabhash

Since Specialization
Citations

This map shows the geographic impact of Kumar Prabhash's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kumar Prabhash with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kumar Prabhash more than expected).

Fields of papers citing papers by Kumar Prabhash

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kumar Prabhash. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kumar Prabhash. The network helps show where Kumar Prabhash may publish in the future.

Co-authorship network of co-authors of Kumar Prabhash

This figure shows the co-authorship network connecting the top 25 collaborators of Kumar Prabhash. A scholar is included among the top collaborators of Kumar Prabhash based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kumar Prabhash. Kumar Prabhash is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
2.
Jha, Prerana, Rohit Mishra, Neha Sharma, et al.. (2025). Circulating tumor DNA profiling for non-invasive genomic analysis in Indian lung cancer patients: A real-world experience. PubMed. 8. 100300–100300. 1 indexed citations
3.
Mahajan, Abhishek, Rajat Agarwal, Richa Vaish, et al.. (2025). A Novel Deep Learning-Based (3D U-Net Model) Automated Pulmonary Nodule Detection Tool for CT Imaging. Current Oncology. 32(2). 95–95.
4.
Kumar, Amit, Akhil Kapoor, Vanita Noronha, et al.. (2024). Lorlatinib in the second line and beyond for ALK positive lung cancer: real-world data from resource-constrained settings. PubMed. 2(1). 35–35. 1 indexed citations
5.
Noronha, Vanita, et al.. (2024). Retrospective analysis: Does 5-FU dose adjustment per DPYD mutation status affect toxicity?. Journal of Clinical Oncology. 42(16_suppl). 11172–11172.
6.
Jha, Prerana, Rohit Mishra, Nandini Menon, et al.. (2024). Identification of Rare EIF3E::RSPO2 Fusion in Recurrent and Aggressive Urachal Adenocarcinoma. Genes Chromosomes and Cancer. 63(6). e23250–e23250. 1 indexed citations
7.
Jha, Prerana, Rohit Mishra, Sewanti Limaye, et al.. (2024). Landscape of Clinically Relevant Genomic Alterations in the Indian Non-small Cell Lung Cancer Patients. Clinical Lung Cancer. 25(8). e420–e430.e20. 2 indexed citations
8.
Singh, Ajay, Vanita Noronha, Nandini Menon, et al.. (2024). Real-World Experience of First-Line Osimertinib in EGFR Mutated Non-Small Cell Lung Cancers from a Tertiary Cancer Center, India. SHILAP Revista de lepidopterología. 14(4). 785–790.
9.
Patil, Vijay, et al.. (2024). Intrathecal pemetrexed in NSCLC patients with leptomeningeal metastasis. ecancermedicalscience. 18. 1792–1792.
11.
Chandrasekharan, Arun, Prabhat Bhargava, Sujay Srinivas, et al.. (2022). Outcomes of Ewing sarcoma in adults over 40 years of age from a low-middle income country. ecancermedicalscience. 16. 1361–1361. 4 indexed citations
12.
Noronha, Vanita, Vijay Patil, Ajay Singh, et al.. (2022). NRAS mutation in differentiated thyroid cancer. Cancer Research Statistics and Treatment. 5(4). 722–727. 2 indexed citations
13.
Rao, Abhijith Rajaram, et al.. (2022). Timed Up and Go as a predictor of mortality in older Indian patients with cancer. Cancer Research Statistics and Treatment. 5(1). 75–82. 4 indexed citations
14.
Rao, Abhijith Rajaram, Shreya Gattani, Renita Castelino, et al.. (2021). Utilization of technology among older Indian patients with cancer: A cross-sectional study. Cancer Research Statistics and Treatment. 4(4). 656–662. 6 indexed citations
15.
Purandare, Nilendu, C.S. Pramesh, George Karimundackal, et al.. (2021). Improving accuracy of 18F-fluorodeoxyglucose PET computed tomography to diagnose nodal involvement in non-small cell lung cancer: utility of using various predictive models. Nuclear Medicine Communications. 42(5). 535–544. 2 indexed citations
16.
Sahay, Ayushi, Rajiv Kumar, Amit Janu, & Kumar Prabhash. (2020). Alk1 gene rearranged pulmonary sarcomatoid carcinoma masquerading as tuberculosis in a young male. Turkish Journal of Pathology. 1(1). 71–77. 1 indexed citations
17.
Prabhash, Kumar, Akhil Kapoor, Vanita Noronha, et al.. (2020). Molecular tumor board: Case 2 – Evolution of resistance in anaplastic lymphoma kinase driven non-small-cell lung carcinoma. Cancer Research Statistics and Treatment. 3(1). 89–89. 4 indexed citations
18.
Prabhash, Kumar, et al.. (2014). Palliative chemotherapy in carcinoma penis: Does platinum and taxane combination holds a promise?. Urology Annals. 6(1). 18–18. 7 indexed citations
20.
Prabhash, Kumar, et al.. (2012). Role of paclitaxel and platinum-based adjuvant chemotherapy in high-risk penile cancer. Urology Annals. 4(3). 150–150. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026